Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life

Table 3

Short form 36, SF-36 (100% ∼Best).

(mean±SD, 𝑛=8)	1st year				2nd year
	Baseline	Week 13	Week 26	Week 52	Washout	Week 13	Week 26	Week 52	P-value
Treatment	None	GLP-2	GLP-2	GLP-2	None	GLP-2	GLP-2 + Cholyl-sarcosine	GLP-2
Physical Function	73±23	76±24	78±24	77±27	75±24	79±22	77±25	78±21	0.51
Limitation based on Physical Function	44±42	72±36	69±40	72±36	44±42	66±40	69±44	63±46	0.34
Physical Pain	82±20	76±32	81±31	80±25	80±23	77±32	79±26	73±37	0.19
General Well-being	51±23	46±20	48±21	48±20	47±29	47±22	49±21	47±20	0.84
Physical Component Summary	43±11	43±9	45±12	43±9	41±10	44±8	43±9	44±10	0.83
Energy	39±31	58±28	51±39	55±33	35±31	47±29	44±31	51±35	0.10
Social Function	83±22	88±27	86±23	88±22	80±25	84±26	81±21	75±35	0.44
Limitation based on Mental Function	71±45	67±40	67±36	83±36	63±42	71±42	79±40	67±36	0.28
Mental Function	70±20	83±18 *	72±26	80±21 *	70±20	73±23 *	75±22 *	76±20 *	0.02
Mental Component Summary	45±13	49±11	48±13	53±11 *	46±12	50±11	51±10	46±14	0.02

* ∼𝑃<.05, Compared to Baseline by Dunnett’s alternatively Bonferoni’s test.